Matthew Gline

Insider Reports History

Location
London
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Gline:

Form 4 holding Director, 10%+ Owner

Arbutus Biopharma Corp

Security class
Common Shares
Shares / value
38,847,462
Estimated value
$127,536,218
Report date
24 Feb 2025
Price
$3.28
Ownership
By Roivant Sciences Ltd.
Form 4 holding CEO, Director

Roivant Sciences Ltd.

Security class
Capped Value Appreciation Rights
Shares / value
0
Estimated value
Report date
30 Mar 2026
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding CEO, Director

Roivant Sciences Ltd.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
15 Dec 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Matthew Gline

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .